205676-86-4 Usage
Uses
Used in Pharmaceutical Industry:
ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is used as a chemical intermediate for the synthesis of various drugs, particularly those that target the central nervous system and the cardiovascular system. Its unique structure and properties make it a key component in the development of medications with potential therapeutic effects on these systems.
Used in Central Nervous System Medications:
In the field of neurology, ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is used as a precursor in the production of medications aimed at treating disorders and conditions related to the central nervous system. Its role in these medications is crucial for their effectiveness in managing symptoms and improving patient outcomes.
Used in Cardiovascular System Medications:
ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE also plays a vital role in the development of drugs targeting the cardiovascular system. Its presence in these medications contributes to their ability to address various heart-related conditions and promote overall cardiovascular health.
Used in Cancer Treatment Research:
In the realm of oncology, ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE has been investigated for its potential use in the treatment of certain types of cancer. Its unique chemical properties make it a promising candidate for further research and development in cancer therapeutics, with the aim of discovering new and effective treatment options for patients.
Overall, ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is a versatile and valuable chemical compound in the pharmaceutical industry, with a wide range of applications and potential for further exploration in the development of new and innovative medications.
Check Digit Verification of cas no
The CAS Registry Mumber 205676-86-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,6,7 and 6 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 205676-86:
(8*2)+(7*0)+(6*5)+(5*6)+(4*7)+(3*6)+(2*8)+(1*6)=144
144 % 10 = 4
So 205676-86-4 is a valid CAS Registry Number.
205676-86-4Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core
Marugán, Juan José,Manthey, Carl,Anaclerio, Beth,Lafrance, Lou,Lu, Tianbao,Markotan, Tom,Leonard, Kristi A.,Crysler, Carl,Eisennagel, Stephen,Dasgupta, Malini,Tomczuk, Bruce
, p. 926 - 934 (2007/10/03)
A novel series of potent and selective αvβ 3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the gua
Vitronectin receptor antagonists
-
, (2008/06/13)
Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
-
, (2008/06/13)
The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable
Method for stimulating bone formation
-
, (2008/06/13)
A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.
Vitronectin receptor antagonists
-
, (2008/06/13)
Compounds of the formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
